BridgeMD
New treatment option for Amyotrophic Lateral Sclerosis (ALS)
Official title Lung Insufflation Capacity Training and Respiratory Function in Amyotrophic Lateral Sclerosis
ClinicalTrials.gov ID: NCT07257302
What this study is testing
- What it's testing
- The goal of this clinical trial is to learn whether lung insufflation capacity (LIC) training can help maintain respiratory function and prolong survival in people with amyotrophic lateral sclerosis (ALS). The main questions it aims to answer are: Does early and continuous LIC training slow the decline in forced vital capacity (FVC)?
- Time commitment: about 36 months
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 and older
You may be able to join if
- Age 20 years or older
- Diagnosis of amyotrophic lateral sclerosis (ALS) according to the El Escorial or Awaji criteria
- Not using noninvasive ventilation (NIV) and without tracheostomy at the start of LIC training
- Able to perform study assessments and provide written informed consent (or assisted signature with communication aid)
You likely can't join if
- Chronic pulmonary disease other than ALS (e.g., COPD, interstitial lung disease)
- Severe cognitive or communication impairment preventing study participation
- Uncontrolled cardiovascular disease, including unstable angina, recent myocardial infarction, decompensated heart failure, serious arrhythmia, severe...
- Uncontrolled hypertension
- Acute systemic illness or fever
- Recent pulmonary embolism, acute cor pulmonale, or severe pulmonary hypertension
See the full eligibility criteria
- Age 20 years or older
- Diagnosis of amyotrophic lateral sclerosis (ALS) according to the El Escorial or Awaji criteria
- Not using noninvasive ventilation (NIV) and without tracheostomy at the start of LIC training
- Able to perform study assessments and provide written informed consent (or assisted signature with communication aid)
- Chronic pulmonary disease other than ALS (e.g., COPD, interstitial lung disease)
- Severe cognitive or communication impairment preventing study participation
- Uncontrolled cardiovascular disease, including unstable angina, recent myocardial infarction, decompensated heart failure, serious arrhythmia, severe aortic stenosis, or active myocarditis/endocarditis
- Uncontrolled hypertension
- Acute systemic illness or fever
- Recent pulmonary embolism, acute cor pulmonale, or severe pulmonary hypertension
- Severe hepatic or renal dysfunction
- Any condition judged inappropriate by the investigator
The study team makes the final eligibility decision.
Where it's taking place
- Kodaira, Tokyo, Japan
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 36 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Kodaira, Tokyo, Japan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.